These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 1350718)

  • 1. Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys.
    Luquin MR; Laguna J; Obeso JA
    Ann Neurol; 1992 May; 31(5):551-4. PubMed ID: 1350718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Yoshimura N; Mizuta E; Yoshida O; Kuno S
    J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
    Gomez-Mancilla B; Bédard PJ
    J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
    Blanchet PJ; Grondin R; Bédard PJ
    Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    Blanchet P; Bédard PJ; Britton DR; Kebabian JW
    J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF; Sheng J
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Bédard PJ; Gomez-Mancilla B; Blanchette P; Gagnon C; Falardeau P; DiPaolo T
    Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
    [No Abstract]   [Full Text] [Related]  

  • 10. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
    Goulet M; Madras BK
    J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of D1 receptor stimulation in normal and MPTP monkeys.
    Bédard PJ; Boucher R
    Neurosci Lett; 1989 Sep; 104(1-2):223-8. PubMed ID: 2573015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
    Gomez-Mancilla B; Bédard PJ
    Exp Neurol; 1992 Aug; 117(2):185-8. PubMed ID: 1354166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
    Silverdale MA; Crossman AR; Brotchie JM
    Exp Neurol; 2002 Mar; 174(1):21-8. PubMed ID: 11869030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
    Blanchet PJ; Calon F; Martel JC; Bédard PJ; Di Paolo T; Walters RR; Piercey MF
    J Pharmacol Exp Ther; 1995 Feb; 272(2):854-9. PubMed ID: 7853204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
    Blanchet PJ; Gomez-Mancilla B; Bédard PJ
    J Neural Transm Suppl; 1995; 45():103-12. PubMed ID: 8748615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
    Nomoto M; Fukuda T
    Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
    J Pharmacol Exp Ther; 1995 Apr; 273(1):309-14. PubMed ID: 7714782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.